Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets. Kite first struck a ...

Kite Pharma and its hotly anticipated CAR-T med nabbed an $11.9 billion buyout offer from Gilead Sciences, which has been shopping for oncology assets to diversify away from its flagging hepatitis.

Kite Pharma and Cell Design Labs said today they will partner to develop next-generation, precision-controlled chimeric antigen receptor (CAR) T-cell immunotherapy candidates using Cell Design ...

In June 2016, Cell Design Labs and what was then independently owned Kite Pharma launched an up-to-$67.5 million collaboration to develop next-generation, precision-controlled CAR-T immunotherapy ...

Gilead's Kite wins FDA nod for new CAR-T manufacturing process to speed up Yescarta turnaround. By Angus Liu Jan 30, 2024 8:39am. Gilead Sciences Kite Pharma CAR-T cell therapy ...

(RTTNews) - Kite's, a Gilead Company (GILD), Yescarta CAR T-cell therapy improved event-free survival by 60% over chemotherapy plus stem cell tran ...

I nvestors wanted Gilead Sciences to shake things up with a big, transformative acquisition and that’s what the company did Monday, agreeing to buy Kite Pharma and its CAR-T cancer-killing ...

With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on the hunt for a new manufacturing site to fuel those hopes.

A federal jury Dec. 13 ordered Gilead Sciences subsidiary Kite Pharma to pay $752 million to Bristol Myers-Squibb subsidiary Juno Therapeutics for allegedly violating a patent when developing its ...

Based on the results of the phase 2 ZUMA-1 trial in patients with refractory non-Hodgkin lymphoma, Kite Pharma has submitted for, and received, a priority review for its chimeric antigen receptor ...

In August 2015, Kite Pharma, Inc. filed an inter partes review in the U.S. Patent & Trademark Office in an attempt to invalidate U.S. Patent No. 7,446,190 by challenging all of its claims.

A federal jury Dec. 13 ordered Gilead Sciences subsidiary Kite Pharma to pay $752 million to Bristol Myers-Squibb subsidiary Juno Therapeutics for allegedly violating a patent when developing its ...